Morgan Stanley analyst Sean Laaman raised the firm’s price target on BeOne Medicines (ONC) to $390 from $383 and keeps an Overweight rating on the shares. Brukinsa came in above Street expectations with the bottom end of total revenue guidance raised to $5.1B-$5.3B, the analyst tells investors in a research note. The firm added that BeOne provided updates across its pipeline, with updated data expected at ASH in December.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines price target raised to $396 from $348 at Citizens JMP
- BeOne Medicines Reports Strong Q3 2025 Growth
- BeOne Medicines: Strong Market Position and Promising Growth Prospects Drive Buy Rating
- BeiGene’s Earnings Call: Record Growth and Positive Outlook
- BeOne Medicines reports Q3 non-GAAP EPS $2.65, consensus 86c